Business Context and Reporting Period
Karyopharm Therapeutics Inc. (KPTI) is a commercial-stage pharmaceutical company focused on the development and commercialization of XPO1 inhibitors, primarily its lead asset XPOVIO (selinexor) for multiple myeloma and myelofibrosis. This Form 10-Q covers the quarterly and six-month periods ended June 30, 2026.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 | Balance Sheet (June 30, 2026) |
|---|---|---|---|
| Total Revenue | $33,432 | $68,498 | - |
| Net Loss | $(67,023) | $(89,415) | - |
| Loss Per Share (Basic/Diluted) | $(2.32) | $(3.51) | - |
| Cash, Cash Equivalents & Investments | - | - | $65,105 |
| Total Debt (Current + Non-Current) | - | - | $250,041 |
| Accumulated Deficit | - | - | $(1,848,914) |
Note: Total Debt includes Senior Secured Term Loan ($125,354), Convertible Senior Notes due 2029 ($98,650), and Convertible Senior Notes due 2028 ($25,937).
Material Changes vs. Prior Period
- Revenue: Total revenue for the six months ended June 30, 2026, increased slightly by 1% ($554k) compared to the prior year period. This was driven by an 18% increase in net product revenue ($59.9M vs $50.7M), partially offset by a 50% decrease in license and other revenue ($8.6M vs $17.2M) due to the expiration of development expense reimbursements from partner Menarini.
- Operating Expenses: Total operating expenses decreased by 6% ($7.8M) year-over-year for the six-month period, primarily due to reduced clinical trial costs as Phase 3 trials transitioned to maintenance phases and lower stock-based compensation.
- Net Loss: Net loss increased by 47% for the six months ended June 30, 2026, compared to the prior year. This increase was primarily driven by a significant rise in "Other expense, net" ($40.1M vs $3.0M), largely attributable to non-cash fair value remeasurements of embedded derivatives and liability-classified warrants.
- Liquidity: Cash and investments decreased from $63.7M at year-end 2025 to $65.1M at June 30, 2026, supported by $48.9M in financing proceeds (private placement and open market sales) which offset operating cash burn of $47.7M.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded there is substantial doubt regarding the Company's ability to continue as a going concern within one year. Current liquidity is projected to fund operations only into September 2026.
- Debt Obligations: A principal payment of $15.8 million is due on September 10, 2026, under the senior secured term loan. Without additional financing or a waiver, this payment would breach the minimum liquidity covenant ($10.0M) and leave insufficient resources for operations. Additionally, ~$10.1M in interest payments are due September 30, 2026.
- Strategic Alternatives: The Company is actively evaluating financing opportunities and strategic alternatives (including potential mergers, sales, or restructurings) with the assistance of financial advisors to extend its cash runway.
- Clinical Updates:
- Myelofibrosis: Plans to submit a supplemental New Drug Application (sNDA) in August 2026 for accelerated approval of selinexor + ruxolitinib, based on the SENTRY trial meeting its primary endpoint for spleen volume reduction.
- Endometrial Cancer: The Phase 3 XPORT-EC-042 trial failed to meet its primary endpoint; the Company does not expect to pursue U.S. regulatory approval for this indication.
- DLBCL: Voluntarily withdrew accelerated approval for Diffuse Large B-Cell Lymphoma due to the infeasibility of completing the confirmatory trial.
- Unusual Items: Significant non-cash charges related to the fair value adjustment of embedded derivatives and warrants impacted the net loss significantly in the current period.
Investor Verification Checklist
- Cash Runway: Verify the status of financing efforts to cover the $15.8M principal payment due September 10, 2026, and subsequent interest obligations.
- Debt Covenants: Monitor compliance with the minimum liquidity covenant ($10M through Oct 2026, rising to $25M thereafter) and the impact of the Forbearance Agreement.
- Regulatory Timeline: Confirm the submission and acceptance of the sNDA for myelofibrosis in August 2026 and the FDA's response regarding the accelerated approval pathway.
- Revenue Sustainability: Assess the impact of the loss of Menarini reimbursement revenue on future cash flows and the ability to offset this with product sales growth.
- Strategic Alternatives: Review any announcements regarding the outcome of the evaluation of strategic alternatives (mergers, asset sales, or bankruptcy protection) if financing is not secured.